174 related articles for article (PubMed ID: 35377770)
41. Effectiveness and Tolerability of THC/CBD Oromucosal Spray for Multiple Sclerosis Spasticity in Italy: First Data from a Large Observational Study.
Trojano M; Vila C
Eur Neurol; 2015; 74(3-4):178-85. PubMed ID: 26571097
[TBL] [Abstract][Full Text] [Related]
42. Refractory trigeminal neuralgia responsive to nabiximols in a patient with multiple sclerosis.
Gajofatto A
Mult Scler Relat Disord; 2016 Jul; 8():64-5. PubMed ID: 27456876
[TBL] [Abstract][Full Text] [Related]
43. Predictors of Nabiximols (Sativex
Carotenuto A; Costabile T; De Lucia M; Moccia M; Falco F; Petruzzo M; De Angelis M; Russo CV; Saccà F; Lanzillo R; Brescia Morra V
J Neurol; 2020 Jun; 267(6):1737-1743. PubMed ID: 32124041
[TBL] [Abstract][Full Text] [Related]
44. Short and long term effects of Nabiximols on balance and walking assessed by 3D-gait analysis in people with Multiple Sclerosis and spasticity.
De Blasiis P; Siani MF; Fullin A; Sansone M; Melone MAB; Sampaolo S; Signoriello E; Lus G
Mult Scler Relat Disord; 2021 Jun; 51():102805. PubMed ID: 33862313
[TBL] [Abstract][Full Text] [Related]
45. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.
Otero-Romero S; Sastre-Garriga J; Comi G; Hartung HP; Soelberg Sørensen P; Thompson AJ; Vermersch P; Gold R; Montalban X
Mult Scler; 2016 Oct; 22(11):1386-1396. PubMed ID: 27207462
[TBL] [Abstract][Full Text] [Related]
46. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
Vermersch P
Expert Rev Neurother; 2011 Apr; 11(4 Suppl):15-9. PubMed ID: 21449855
[TBL] [Abstract][Full Text] [Related]
47. The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.
Celius EG; Vila C
Brain Behav; 2018 May; 8(5):e00962. PubMed ID: 29761015
[TBL] [Abstract][Full Text] [Related]
48. Effect of nabiximols oromucosal spray (Sativex
Garde N; Heibel M
Drugs Context; 2024; 13():. PubMed ID: 38384931
[TBL] [Abstract][Full Text] [Related]
49. Nabiximols oromucosal spray in patients with multiple sclerosis-related bladder dysfunction: A prospective study.
Torri Clerici V; Brambilla L; Politi PL; Viggiani F; Mercurio S; Tonietti S; Ronzoni M; Crisafulli SG; Antozzi C; Tramacere I; Redemagni C; Confalonieri P
Mult Scler Relat Disord; 2023 Jun; 74():104711. PubMed ID: 37062198
[TBL] [Abstract][Full Text] [Related]
50. Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.
Mallada Frechín J
Neurodegener Dis Manag; 2018 Jun; 8(3):151-159. PubMed ID: 29851356
[TBL] [Abstract][Full Text] [Related]
51. THC/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study.
Maniscalco GT; Aponte R; Bruzzese D; Guarcello G; Manzo V; Napolitano M; Moreggia O; Chiariello F; Florio C
Neurol Sci; 2018 Jan; 39(1):97-102. PubMed ID: 29052091
[TBL] [Abstract][Full Text] [Related]
52. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
Syed YY; McKeage K; Scott LJ
Drugs; 2014 Apr; 74(5):563-78. PubMed ID: 24671907
[TBL] [Abstract][Full Text] [Related]
53. THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms.
Trojano M
Eur Neurol; 2016; 75 Suppl 1():4-8. PubMed ID: 26901343
[TBL] [Abstract][Full Text] [Related]
54. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.
Pozzilli C
Expert Rev Neurother; 2013 Dec; 13(12 Suppl):49-54. PubMed ID: 24289844
[TBL] [Abstract][Full Text] [Related]
55. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.
Serpell MG; Notcutt W; Collin C
J Neurol; 2013 Jan; 260(1):285-95. PubMed ID: 22878432
[TBL] [Abstract][Full Text] [Related]
56. Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence.
Ziemssen T
Neurodegener Dis Manag; 2019 Apr; 9(2s):1-2. PubMed ID: 30657019
[TBL] [Abstract][Full Text] [Related]
57. Clinical case reviews in multiple sclerosis spasticity: experiences from around Europe.
Koehler J; Amato MP; Oreja-Guevara C; Lycke J
Expert Rev Neurother; 2013 Dec; 13(12 Suppl):61-6. PubMed ID: 24289846
[TBL] [Abstract][Full Text] [Related]
58. Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation.
Giacoppo S; Bramanti P; Mazzon E
Mult Scler Relat Disord; 2017 Oct; 17():22-31. PubMed ID: 29055461
[TBL] [Abstract][Full Text] [Related]
59. Sativex for the management of multiple sclerosis symptoms.
Perras C
Issues Emerg Health Technol; 2005 Sep; (72):1-4. PubMed ID: 16317825
[TBL] [Abstract][Full Text] [Related]
60. Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from postapproval pragmatic studies.
Patti F
Neurodegener Dis Manag; 2019 Apr; 9(2s):3-7. PubMed ID: 30657027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
